Skeletal muscle cells actively shape (auto)immune responses

Autoimmunity Reviews

Volumn 17, Issue 5, 2018, Pages 518-529

  Afzali, Ali Maisam ^a,b   Müntefering, Thomas ^b   Wiendl, Heinz ^b   Meuth, Sven G ^b   Ruck, Tobias ^b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Chemokines; Cytokines; Immunobiology; Inflammatory myopathies; Myositis; T cell costimulatory molecules

Indexed keywords

DEFENSIN; PATHOGEN RECOGNITION RECEPTOR; RECEPTOR; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; AUTOIMMUNITY; CELL SURFACE; HUMAN; INNATE IMMUNITY; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; REVIEW; SKELETAL MUSCLE CELL; IMMUNOLOGY; SKELETAL MUSCLE;

AUTOIMMUNITY; HUMANS; MUSCLE, SKELETAL;

EID: 85043530500     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2017.12.005     Document Type: Review

References (148)

1. Unverricht, H., Über eine eigenthümliche Form von akuter Muskelentzündung mit einem der Trichinose ähnelnden Krankheitsbilde. Münch Med Wochenschr 34 (1887), 488–492.
2. Wagner, E., Fall einer seltenen Muskelkrankheit. Arch Heilkd, 4, 1863, 282.
3. Dalakas, M.C., Mechanisms of disease: signaling pathways and immunobiology of inflammatory myopathies. Nat Clin Pract Rheumatol 2 (2006), 219–227.
4. Dalakas, M.C., Hohlfeld, R., Polymyositis and dermatomyositis. Lancet 362 (2003), 971–982.
5. Wiendl, H., Hohlfeld, R., Kieseier, B.C., Immunobiology of muscle: advances in understanding an immunological microenvironment. Trends Immunol 26 (2005), 373–380.
6. Wiendl, H., Hohlfeld, R., Kieseier, B.C., Muscle-derived positive and negative regulators of the immune response. Curr Opin Rheumatol 17 (2005), 714–719.
7. Irintchev, M.Z.A., Starzinski-Powitz, A., Wernig, A., Expression pattern of M-cadherin in normal, denervated and regenerating mouse muscles. Dev Dyn, 199, 1994, 326437.
8. Mantegazza, R., Bernasconi, P., Cellular aspects of myositis. Curr Opin Rheumatol 6 (1994), 568–574.
9. Nagaraju, K., Immunological capabilities of skeletal muscle cells. Acta Physiol Scand 171 (2001), 215–223.
10. Hohlfeld, R., Engel, A.G., Goebels, N., Behrens, L., Cellular immune mechanisms in inflammatory myopathies. Curr Opin Rheumatol 9 (1997), 520–526.
11. Ruck, T., Bittner, S., Afzali, A.M., Gobel, K., Glumm, S., Kraft, P., et al. The NKG2D - IL- 15 signaling pathway contributes to T-cell mediated pathology in inflammatory myopathies. Autoimmun Rev 16:5 (May 2017), 478–494.
12. De Paepe, B., Creus, K.K., De Bleecker, J.L., Role of cytokines and chemokines in idiopathic inflammatory myopathies. Curr Opin Rheumatol 21 (2009), 610–616.
13. Figarella-Branger, D., Civatte, M., Bartoli, C., Pellissier, J.-F., Cytokines, chemokines, and cell adhesion molecules in inflammatory myopathies. Muscle Nerve 28 (2003), 659–682.
14. Afzali, A.M., Ruck, T., Wiendl, H., Meuth, S.G., Animal models in idiopathic inflammatory myopathies: how to overcome a translational roadblock?. Autoimmun Rev 16 (2017), 478–494.
15. Medzhitov, R., Janeway, C. Jr., Innate immunity. N Engl J Med 343 (2000), 338–344.
16. Rohrl, J., Yang, D., Oppenheim, J.J., Hehlgans, T., Human beta-defensin 2 and 3 and their mouse orthologs induce chemotaxis through interaction with CCR2. J Immunol 184 (2010), 6688–6694.
17. Cappelletti, C., Baggi, F., Zolezzi, F., Biancolini, D., Beretta, O., Severa, M., et al. Type I interferon and Toll-like receptor expression characterizes inflammatory myopathies. Neurology 76 (2011), 2079–2088.
18. Guttsches, A.K., Jacobsen, F., Theiss, C., Rittig, A., Rehimi, R., Kley, R.A., et al. Human beta-defensin-3 correlates with muscle fibre degeneration in idiopathic inflammatory myopathies. Innate Immun. 20 (2014), 49–60.
19. Tournadre, A., Lenief, V., Miossec, P., Expression of Toll-like receptor 3 and Toll-like receptor 7 in muscle is characteristic of inflammatory myopathy and is differentially regulated by Th1 and Th17 cytokines. Arthritis Rheum 62 (2010), 2144–2151.
20. Yang, D., Chertov, O., Bykovskaia, S.N., Chen, Q., Buffo, M.J., Shogan, J., et al. Beta-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. Science 286 (1999), 525–528.
21. Boyd, J.H., Divangahi, M., Yahiaoui, L., Gvozdic, D., Qureshi, S., Petrof, B.J., Toll-like receptors differentially regulate CC and CXC chemokines in skeletal muscle via NF-kappaB and calcineurin. Infect Immun 74 (2006), 6829–6838.
22. Frost, R.A., Nystrom, G.J., Lang, C.H., Lipopolysaccharide stimulates nitric oxide synthase-2 expression in murine skeletal muscle and C(2)C(12) myoblasts via Toll-like receptor-4 and c-Jun NH(2)-terminal kinase pathways. Am J Physiol Cell Physiol, 287, 2004 (C1605-15).
23. Schreiner, B., Voss, J., Wischhusen, J., Dombrowski, Y., Steinle, A., Lochmuller, H., et al. Expression of toll-like receptors by human muscle cells in vitro and in vivo: TLR3 is highly expressed in inflammatory and HIV myopathies, mediates IL-8 release and up-regulation of NKG2D-ligands. FASEB J. 20 (2006), 118–120.
24. Tournadre, A., Lenief, V., Eljaafari, A., Miossec, P., Immature muscle precursors are a source of interferon-beta in myositis: role of Toll-like receptor 3 activation and contribution to HLA class I up-regulation. Arthritis Rheum 64 (2012), 533–541.
25. Miller, S.I., Ernst, R.K., Bader, M.W., LPS, TLR4 and infectious disease diversity. Nat Rev Microbiol 3 (2005), 36–46.
26. Frost, R.A., Nystrom, G.J., Lang, C.H., Multiple Toll-like receptor ligands induce an IL-6 transcriptional response in skeletal myocytes. Am J Physiol Regul Integr Comp Physiol, 290, 2006 (R773-84).
27. Verma, R., Bharti, K., Toll like receptor 3 and viral infections of nervous system. J Neurol Sci 372 (2017), 40–48.
28. De Paepe, B., Interferons as components of the complex web of reactions sustaining inflammation in idiopathic inflammatory myopathies. Cytokine 74 (2015), 81–87.
29. Harlow, L., Fernandez, I., Soejima, M., Ridgway, W.M., Ascherman, D.P., Characterization of TLR4-mediated auto-antibody production in a mouse model of histidyl-tRNA synthetase-induced myositis. Innate Immun 18 (2012), 876–885.
30. Howard, O.M.Z., Dong, H.F., Yang, D., Raben, N., Nagaraju, K., Rosen, A., et al. Histidyl–tRNA synthetase and asparaginyl–tRNA synthetase, autoantigens in myositis, activate chemokine receptors on T lymphocytes and immature dendritic cells. J Exp Med 196 (2002), 781–791.
31. Soejima, M., Kang, E.H., Gu, X., Katsumata, Y., Clemens, P.R., Ascherman, D.P., Role of innate immunity in a murine model of histidyl-transfer RNA synthetase (Jo-1)-mediated myositis. Arthritis Rheum 63 (2011), 479–487.
32. Grundtman, C., Bruton, J., Yamada, T., Östberg, T., Pisetsky, D.S., Harris, H.E., et al. Effects of HMGB1 on in vitro responses of isolated muscle fibers and functional aspects in skeletal muscles of idiopathic inflammatory myopathies. FASEB J 24 (2010), 570–578.
33. Wan, Z., Zhang, X., Peng, A., He, M., Lei, Z., Wang, Y., TLR4-HMGB1 signaling pathway affects the inflammatory reaction of autoimmune myositis by regulating MHC-I. Int Immunopharmacol 41 (2016), 74–81.
34. Zong, M., Bruton, J.D., Grundtman, C., Yang, H., Li, J.H., Alexanderson, H., et al. TLR4 as receptor for HMGB1 induced muscle dysfunction in myositis. Ann Rheum Dis 72 (2013), 1390–1399.
35. Drenth, J.P., van der Meer, J.W., The inflammasome–a linebacker of innate defense. N Engl J Med 355 (2006), 730–732.
36. Strowig, T., Henao-Mejia, J., Elinav, E., Flavell, R., Inflammasomes in health and disease. Nature 481 (2012), 278–286.
37. Yin, X., Han, G.C., Jiang, X.W., Shi, Q., Pu, C.Q., Increased expression of the NOD-like receptor family, pyrin domain containing 3 inflammasome in dermatomyositis and polymyositis is a potential contributor to their pathogenesis. Chin Med J 129 (2016), 1047–1052.
38. Rawat, R., Cohen, T.V., Ampong, B., Francia, D., Henriques-Pons, A., Hoffman, E.P., et al. Inflammasome up-regulation and activation in dysferlin-deficient skeletal muscle. Am J Pathol 176 (2010), 2891–2900.
39. Bender, A., Ernst, N., Iglesias, A., Dornmair, K., Wekerle, H., Hohlfeld, R., T cell receptor repertoire in polymyositis: clonal expansion of autoaggressive CD8+ T cells. J Exp Med 181 (1995), 1863–1868.
40. Fyhr, I.M., Moslemi, A.R., Lindberg, C., Oldfors, A., T cell receptor beta-chain repertoire in inclusion body myositis. J Neuroimmunol 91 (1998), 129–134.
41. O'Hanlon, T.P., Dalakas, M.C., Plotz, P.H., Miller, F.W., Predominant TCR-alpha beta variable and joining gene expression by muscle-infiltrating lymphocytes in the idiopathic inflammatory myopathies. J Immunol 152 (1994), 2569–2576.
42. Salajegheh, M., Rakocevic, G., Raju, R., Shatunov, A., Goldfarb, L.G., Dalakas, M.C., T cell receptor profiling in muscle and blood lymphocytes in sporadic inclusion body myositis. Neurology 69 (2007), 1672–1679.
43. Bao, S.S., King, N.J., dos Remedios, C.G., Elevated MHC class I and II antigens in cultured human embryonic myoblasts following stimulation with gamma-interferon. Immunol Cell Biol 68:Pt 4 (1990), 235–241.
44. Goebels, N., Michaelis, D., Wekerle, H., Hohlfeld, R., Human myoblasts as antigen-presenting cells. J Immunol 149 (1992), 661–667.
45. Karpati, G., Pouliot, Y., Carpenter, S., Expression of immunoreactive major histocompatibility complex products in human skeletal muscles. Ann Neurol 23 (1988), 64–72.
46. Michaelis, D., Goebels, N., Hohlfeld, R., Constitutive and cytokine-induced expression of human leukocyte antigens and cell adhesion molecules by human myotubes. Am J Pathol 143 (1993), 1142–1149.
47. Emslie-Smith, A.M., Arahata, K., Engel, A.G., Major histocompatibility complex class I antigen expression, immunolocalization of interferon subtypes, and T cell-mediated cytotoxicity in myopathies. Hum Pathol 20 (1989), 224–231.
48. McDouall, R.M., Dunn, M.J., Dubowitz, V., Expression of class I and class II MHC antigens in neuromuscular diseases. J Neurol Sci 89 (1989), 213–226.
49. Nagaraju, K., Casciola-Rosen, L., Lundberg, I., Rawat, R., Cutting, S., Thapliyal, R., et al. Activation of the endoplasmic reticulum stress response in autoimmune myositis: potential role in muscle fiber damage and dysfunction. Arthritis Rheum 52 (2005), 1824–1835.
50. Nagaraju, K., Raben, N., Loeffler, L., Parker, T., Rochon, P.J., Lee, E., et al. Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies. Proc Natl Acad Sci U S A 97 (2000), 9209–9214.
51. Coley, W., Rayavarapu, S., Pandey, G.S., Sabina, R.L., Van der Meulen, J.H., Ampong, B., et al. The molecular basis of skeletal muscle weakness in a mouse model of inflammatory myopathy. Arthritis Rheum 64 (2012), 3750–3759.
52. Coley, W., Rayavarapu, S., van der Meulen, J.H., Duba, A.S., Nagaraju, K., Daily supplementation of D-ribose shows no therapeutic benefits in the MHC-I transgenic mouse model of inflammatory myositis. PLoS One, 8, 2013, e65970.
53. Freret, M., Drouot, L., Obry, A., Ahmed-Lacheheb, S., Dauly, C., Adriouch, S., et al. Overexpression of MHC class I in muscle of lymphocyte-deficient mice causes a severe myopathy with induction of the unfolded protein response. Am J Pathol 183 (2013), 893–904.
54. Englund, P., Lindroos, E., Nennesmo, I., Klareskog, L., Lundberg, I.E., Skeletal muscle fibers express major histocompatibility complex class II antigens independently of inflammatory infiltrates in inflammatory myopathies. Am J Pathol 159 (2001), 1263–1273.
55. Wiendl, H., Lautwein, A., Mitsdorffer, M., Krause, S., Erfurth, S., Wienhold, W., et al. Antigen processing and presentation in human muscle: cathepsin S is critical for MHC class II expression and upregulated in inflammatory myopathies. J Neuroimmunol 138 (2003), 132–143.
56. Bhattarai, S., Ghannam, K., Krause, S., Benveniste, O., Marg, A., de Bruin, G., et al. The immunoproteasomes are key to regulate myokines and MHC class I expression in idiopathic inflammatory myopathies. J Autoimmun 75 (2016), 118–129.
57. Ghannam, K., Martinez-Gamboa, L., Spengler, L., Krause, S., Smiljanovic, B., Bonin, M., et al. Upregulation of immunoproteasome subunits in myositis indicates active inflammation with involvement of antigen presenting cells, CD8 T-cells and IFNGamma. PloS One, 9, 2014, e104048.
58. Keller, C.W., Fokken, C., Turville, S.G., Lunemann, A., Schmidt, J., Munz, C., et al. TNF-alpha induces macroautophagy and regulates MHC class II expression in human skeletal muscle cells. J Biol Chem 286 (2011), 3970–3980.
59. Wiendl, H., Behrens, L., Maier, S., Johnson, M.A., Weiss, E.H., Hohlfeld, R., Muscle fibers in inflammatory myopathies and cultured myoblasts express the nonclassical major histocompatibility antigen HLA-G. Ann Neurol 48 (2000), 679–684.
60. Ferreira, L.M., Meissner, T.B., Tilburgs, T., Strominger, J.L., HLA-G: at the interface of maternal-fetal tolerance. Trends Immunol 38:4 (Apr. 2017), 272–286.
61. Rajagopalan, S., Long, E.O., A human histocompatibility leukocyte antigen (HLA)-G-specific receptor expressed on all natural killer cells. J Exp Med 189 (1999), 1093–1100.
62. Waschbisch, A., Meuth, S.G., Herrmann, A.M., Wrobel, B., Schwab, N., Lochmuller, H., et al. Intercellular exchanges of membrane fragments (trogocytosis) between human muscle cells and immune cells: a potential mechanism for the modulation of muscular immune responses. J Neuroimmunol 209 (2009), 131–138.
63. Janeway, C.A., Bottomly, K., Signals and signs for lymphocyte-responses. Cell 76 (1994), 275–285.
64. Bartoccioni, E., Gallucci, S., Scuderi, F., Ricci, E., Servidei, S., Broccolini, A., et al. MHC class I, MHC class II and intercellular adhesion molecule-1 (ICAM-1) expression in inflammatory myopathies. Clin Exp Immunol 95 (1994), 166–172.
65. Beauchamp, J.R., Abraham, D.J., Bou-Gharios, G., Partridge, T.A., Olsen, I., Expression and function of heterotypic adhesion molecules during differentiation of human skeletal muscle in culture. Am J Pathol 140 (1992), 387–401.
66. De Bleecker, J.L., Engel, A.G., Expression of cell adhesion molecules in inflammatory myopathies and Duchenne dystrophy. J Neuropathol Exp Neurol 53 (1994), 369–376.
67. Ito, T., Kumamoto, T., Horinouchi, H., Yukishige, K., Sugihara, R., Fujimoto, S., et al. Adhesion molecule expression in experimental myositis. Muscle Nerve 25 (2002), 409–418.
68. Marino, M., Scuderi, F., Mannella, F., Bartoccioni, E., TGF-beta 1 and IL-10 modulate IL-1 beta-induced membrane and soluble ICAM-1 in human myoblasts. J Neuroimmunol 134 (2003), 151–157.
69. Marino, M., Scuderi, F., Mazzarelli, P., Mannella, F., Provenzano, C., Bartoccioni, E., Constitutive and cytokine-induced expression of MHC and intercellular adhesion molecule-1 (ICAM-1) on human myoblasts. J Neuroimmunol 116 (2001), 94–101.
70. Sallum, A.M., Kiss, M.H., Silva, C.A., Wakamatsu, A., Vianna, M.A., Sachetti, S., et al. Difference in adhesion molecule expression (ICAM-1 and VCAM-1) in juvenile and adult dermatomyositis, polymyositis and inclusion body myositis. Autoimmun Rev 5 (2006), 93–100.
71. Kalovidouris, A.E., Horn, C.A., Plotkin, Z., The role of cytokines in polymyositis III. Recombinant human interferon-gamma enhances T cell adhesion to cultured human muscle cells. Arthritis Rheum. 37 (1994), 907–914.
72. Kumamoto, T., Abe, T., Ueyama, H., Sugihara, R., Shigenaga, T., Tsuda, T., Elevated soluble intercellular adhesion molecules-1 in inflammatory myopathy. Acta Neurol Scand 95 (1997), 34–37.
73. Behrens, L., Kerschensteiner, M., Misgeld, T., Goebels, N., Wekerle, H., Hohlfeld, R., Human muscle cells express a functional costimulatory molecule distinct from B7.1 (CD80) and B7.2 (CD86) in vitro and in inflammatory lesions. J Immunol 161 (1998), 5943–5951.
74. Bernasconi, P., Confalonieri, P., Andreetta, F., Baggi, F., Cornelio, F., Mantegazza, R., The expression of co-stimulatory and accessory molecules on cultured human muscle cells is not dependent on stimulus by pro-inflammatory cytokines: relevance for the pathogenesis of inflammatory myopathy. J Neuroimmunol 85 (1998), 52–58.
75. Murata, K., Dalakas, M.C., Expression of the costimulatory molecule BB-1, the ligands CTLA-4 and CD28, and their mRNA in inflammatory myopathies. Am J Pathol 155 (1999), 453–460.
76. Schmidt, J., Rakocevic, G., Raju, R., Dalakas, M.C., Upregulated inducible co-stimulator (ICOS) and ICOS-ligand in inclusion body myositis muscle: significance for CD8+ T cell cytotoxicity. Brain 127 (2004), 1182–1190.
77. Wiendl, H., Mitsdoerffer, M., Schneider, D., Melms, A., Lochmuller, H., Hohlfeld, R., et al. Muscle fibres and cultured muscle cells express the B7.1/2-related inducible co-stimulatory molecule, ICOSL: implications for the pathogenesis of inflammatory myopathies. Brain 126 (2003), 1026–1035.
78. Katsumata, Y., Ridgway, W.M., Oriss, T., Gu, X., Chin, D., Wu, Y., et al. Species-specific immune responses generated by histidyl-tRNA synthetase immunization are associated with muscle and lung inflammation. J Autoimmun 29 (2007), 174–186.
79. Banchereau, J., Bazan, F., Blanchard, D., Briere, F., Galizzi, J.P., van Kooten, C., et al. The CD40 antigen and its ligand. Annu Rev Immunol 12 (1994), 881–922.
80. Van Kooten, C., Banchereau, J., CD40-CD40 ligand: a multifunctional receptor-ligand pair. Adv Immunol 61 (1996), 1–77.
81. Grewal, I.S., Flavell, R.A., The role of CD40 ligand in costimulation and T-cell activation. Immunol Rev 153 (1996), 85–106.
82. Sugiura, T., Kawaguchi, Y., Harigai, M., Takagi, K., Ohta, S., Fukasawa, C., et al. Increased CD40 expression on muscle cells of polymyositis and dermatomyositis: role of CD40-CD40 ligand interaction in IL-6, IL-8, IL-15, and monocyte chemoattractant protein-1 production. J Immunol 164 (2000), 6593–6600.
83. Meresse, B., Chen, Z., Ciszewski, C., Tretiakova, M., Bhagat, G., Krausz, T.N., et al. Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in celiac disease. Immunity 21 (2004), 357–366.
84. Wiendl, H., Mitsdoerffer, M., Schneider, D., Chen, L., Lochmuller, H., Melms, A., et al. Human muscle cells express a B7-related molecule, B7-H1, with strong negative immune regulatory potential: a novel mechanism of counterbalancing the immune attack in idiopathic inflammatory myopathies. FASEB J 17 (2003), 1892–1894.
85. Xiaoyu, D., Yunxia, W., Qi, F., Dapeng, W., Xiuying, C., Jianhua, J., et al. Expression of B7-homolog 1 in polymyositis. Ann Clin Lab Sci 41 (2011), 154–160.
86. Waschbisch, A., Wintterle, S., Lochmuller, H., Walter, M.C., Wischhusen, J., Kieseier, B.C., et al. Human muscle cells express the costimulatory molecule B7-H3, which modulates muscle-immune interactions. Arthritis Rheum 58 (2008), 3600–3608.
87. Adams, E.M., Kirkley, J., Eidelman, G., Dohlman, J., Plotz, P.H., The predominance of beta (CC) chemokine transcripts in idiopathic inflammatory muscle diseases. Proc Assoc Am Physicians 109 (1997), 275–285.
88. Lepidi, H., Frances, V., Figarella-Branger, D., Bartoli, C., Machado-Baeta, A., Pellissier, J.F., Local expression of cytokines in idiopathic inflammatory myopathies. Neuropathol Appl Neurobiol 24 (1998), 73–79.
89. Lundberg, I., Brengman, J.M., Engel, A.G., Analysis of cytokine expression in muscle in inflammatory myopathies, Duchenne dystrophy, and non-weak controls. J Neuroimmunol 63 (1995), 9–16.
90. Lundberg, I., Ulfgren, A.K., Nyberg, P., Andersson, U., Klareskog, L., Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies. Arthritis Rheum 40 (1997), 865–874.
91. Tews, D.S., Goebel, H.H., Cytokine expression profile in idiopathic inflammatory myopathies. J Neuropathol Exp Neurol 55 (1996), 342–347.
92. Andreetta, F., Bernasconi, P., Torchiana, E., Baggi, F., Cornelio, F., Mantegazza, R., T-cell infiltration in polymyositis is characterized by coexpression of cytotoxic and T-cell-activating cytokine transcripts. Ann N Y Acad Sci 756 (1995), 418–420.
93. De Rossi, M., Bernasconi, P., Baggi, F., de Waal Malefyt, R., Mantegazza, R., Cytokines and chemokines are both expressed by human myoblasts: possible relevance for the immune pathogenesis of muscle inflammation. Int Immunol 12 (2000), 1329–1335.
94. Nagaraju, K., Raben, N., Villalba, M.L., Danning, C., Loeffler, L.A., Lee, E., et al. Costimulatory markers in muscle of patients with idiopathic inflammatory myopathies and in cultured muscle cells. Clin Immunol 92 (1999), 161–169.
95. Guo, X., Higgs, B.W., Rebelatto, M., Zhu, W., Greth, W., Yao, Y., et al. Suppression of soluble T cell-associated proteins by an anti-interferon-alpha monoclonal antibody in adult patients with dermatomyositis or polymyositis. Rheumatology (Oxford) 53 (2014), 686–695.
96. Higgs, B.W., Zhu, W., Morehouse, C., White, W.I., Brohawn, P., Guo, X., et al. A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-alpha monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients. Ann Rheum Dis 73 (2014), 256–262.
97. Yoshihashi-Nakazato, Y., Kawahata, K., Kimura, N., Miyasaka, N., Kohsaka, H., Interferon-gamma, but not interleukin-4, suppresses experimental polymyositis. Arthritis Rheumatol 68 (2016), 1505–1510.
98. Sugihara, T., Okiyama, N., Watanabe, N., Miyasaka, N., Kohsaka, H., Interleukin-1 and tumor necrosis factor alpha blockade treatment of experimental polymyositis in mice. Arthritis Rheum 64 (2012), 2655–2662.
99. Grundtman, C., Malmstrom, V., Lundberg, I.E., Immune mechanisms in the pathogenesis of idiopathic inflammatory myopathies. Arthritis Res Ther, 9, 2007, 208.
100. Schmidt, J., Barthel, K., Wrede, A., Salajegheh, M., Bahr, M., Dalakas, M.C., Interrelation of inflammation and APP in sIBM: IL-1 beta induces accumulation of beta-amyloid in skeletal muscle. Brain 131 (2008), 1228–1240.
101. Baron, P., Galimberti, D., Meda, L., Scarpini, E., Conti, G., Cogiamanian, F., et al. Production of IL-6 by human myoblasts stimulated with Abeta: relevance in the pathogenesis of IBM. Neurology 57 (2001), 1561–1565.
102. Gallucci, S., Provenzano, C., Mazzarelli, P., Scuderi, F., Bartoccioni, E., Myoblasts produce IL-6 in response to inflammatory stimuli. Int. Immunol. 10 (1998), 267–273.
103. Narazaki, M., Hagihara, K., Shima, Y., Ogata, A., Kishimoto, T., Tanaka, T., Therapeutic effect of tocilizumab on two patients with polymyositis. Rheumatology 50 (2011), 1344–1346.
104. Okiyama, N., Sugihara, T., Iwakura, Y., Yokozeki, H., Miyasaka, N., Kohsaka, H., Therapeutic effects of interleukin-6 blockade in a murine model of polymyositis that does not require interleukin-17A. Arthritis Rheum 60 (2009), 2505–2512.
105. Scuderi, F., Mannella, F., Marino, M., Provenzano, C., Bartoccioni, E., IL-6-deficient mice show impaired inflammatory response in a model of myosin-induced experimental myositis. J Neuroimmunol 176 (2006), 9–15.
106. Huang, P.L., Hou, M.S., Wang, S.W., Chang, C.L., Liou, Y.H., Liao, N.S., Skeletal muscle interleukin 15 promotes CD8(+) T-cell function and autoimmune myositis. Skelet Muscle, 5, 2015, 33.
107. Zong, M., Loell, I., Lindroos, E., Nader, G.A., Alexanderson, H., Hallengren, C.S., et al. Effects of immunosuppressive treatment on interleukin-15 and interleukin-15 receptor alpha expression in muscle tissue of patients with polymyositis or dermatomyositis. Ann. Rheum. Dis. 71 (2012), 1055–1063.
108. Sugiura, T., Harigai, M., Kawaguchi, Y., Takagi, K., Fukasawa, C., Ohsako-Higami, S., et al. Increased IL-15 production of muscle cells in polymyositis and dermatomyositis. Int Immunol 14 (2002), 917–924.
109. Yan, W., Fan, W., Chen, C., Wu, Y., Fan, Z., Chen, J., et al. IL-15 up-regulates the MMP-9 expression levels and induces inflammatory infiltration of macrophages in polymyositis through regulating the NF-kB pathway. Gene 591 (2016), 137–147.
110. Civatte, M., Bartoli, C., Schleinitz, N., Chetaille, B., Pellissier, J.F., Figarella-Branger, D., Expression of the beta chemokines CCL3, CCL4, CCL5 and their receptors in idiopathic inflammatory myopathies. Neuropathol Appl Neurobiol 31 (2005), 70–79.
111. Confalonieri, P., Bernasconi, P., Megna, P., Galbiati, S., Cornelio, F., Mantegazza, R., Increased expression of beta-chemokines in muscle of patients with inflammatory myopathies. J Neuropathol Exp Neurol 59 (2000), 164–169.
112. De Bleecker, J.L., De Paepe, B., Vanwalleghem, I.E., Schroder, J.M., Differential expression of chemokines in inflammatory myopathies. Neurology 58 (2002), 1779–1785.
113. De Paepe, B., Creus, K.K., De Bleecker, J.L., Chemokine profile of different inflammatory myopathies reflects humoral versus cytotoxic immune responses. Ann N Y Acad Sci 1109 (2007), 441–453.
114. De Paepe, B., De Bleecker, J.L., Beta-chemokine receptor expression in idiopathic inflammatory myopathies. Muscle Nerve 31 (2005), 621–627.
115. De Paepe, B., De Keyzer, K., Martin, J.-J., De Bleecker, J.L., Alpha-chemokine receptors CXCR1–3 and their ligands in idiopathic inflammatory myopathies. Acta Neuropathol. 109 (2005), 576–582.
116. Bartoli, C., Civatte, M., Pellissier, J., Figarella-Branger, D., CCR2A and CCR2B, the two isoforms of the monocyte chemoattractant protein-1 receptor are up-regulated and expressed by different cell subsets in idiopathic inflammatory myopathies. Acta Neuropathol. 102 (2001), 385–392.
117. Tateyama, M., Fujihara, K., Misu, T., Feng, J., Onodera, Y., Itoyama, Y., Expression of CCR7 and its ligands CCL19/CCL21 in muscles of polymyositis. J Neurol Sci 249 (2006), 158–165.
118. Crescioli, C., Sottili, M., Bonini, P., Cosmi, L., Chiarugi, P., Romagnani, P., et al. Inflammatory response in human skeletal muscle cells: CXCL10 as a potential therapeutic target. Eur J Cell Biol 91 (2012), 139–149.
119. Confalonieri, P., Bernasconi, P., Cornelio, F., Mantegazza, R., Transforming growth factor-beta 1 in polymyositis and dermatomyositis correlates with fibrosis but not with mononuclear cell infiltrate. J Neuropathol Exp Neurol 56 (1997), 479–484.
120. Reimann, J., Schnell, S., Schwartz, S., Kappes-Horn, K., Dodel, R., Bacher, M., Macrophage migration inhibitory factor in normal human skeletal muscle and inflammatory myopathies. J Neuropathol Exp Neurol 69 (2010), 654–662.
121. Schoser, B.G., Blottner, D., Stuerenburg, H.J., Matrix metalloproteinases in inflammatory myopathies: enhanced immunoreactivity near atrophic myofibers. Acta Neurol Scand 105 (2002), 309–313.
122. Choi, Y.C., Dalakas, M.C., Expression of matrix metalloproteinases in the muscle of patients with inflammatory myopathies. Neurology 54 (2000), 65–71.
123. Dehmel, T., Janke, A., Hartung, H.P., Goebel, H.H., Wiendl, H., Kieseier, B.C., The cell-specific expression of metalloproteinase-disintegrins (ADAMs) in inflammatory myopathies. Neurobiol Dis 25 (2007), 665–674.
124. Kieseier, B.C., Schneider, C., Clements, J.M., Gearing, A.J., Gold, R., Toyka, K.V., et al. Expression of specific matrix metalloproteinases in inflammatory myopathies. Brain 124 (2001), 341–351.
125. Cheng, C.S., El-Abd, Y., Bui, K., Hyun, Y.E., Hughes, R.H., Kraus, W.E., et al. Conditions that promote primary human skeletal myoblast culture and muscle differentiation in vitro. Am J Physiol Cell Physiol 306 (2014), C385–95.
126. Knedlitschek, G., Schneider, F., Gottwald, E., Schaller, T., Eschbach, E., Weibezahn, K.F., A tissue-like culture system using microstructures: influence of extracellular matrix material on cell adhesion and aggregation. J Biomech Eng 121 (1999), 35–39.
127. Mahoney, K.M., Rennert, P.D., Freeman, G.J., Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov 14 (2015), 561–584.
128. Stubgen, J.P., Targeted immunotherapy trials for idiopathic inflammatory myopathies. J Neurol. 260 (2013), 368–385.
129. Afzali, A.M., Ruck, T., Herrmann, A.M., Iking, J., Sommer, C., Kleinschnitz, C., et al. The potassium channels TASK2 and TREK1 regulate functional differentiation of murine skeletal muscle cells. Am J Physiol Cell Physiol 311 (2016), C583–C595.
130. Baumert, P., Lake, M.J., Stewart, C.E., Drust, B., Erskine, R.M., Genetic variation and exercise-induced muscle damage: implications for athletic performance, injury and ageing. Eur J Appl Physiol 116 (2016), 1595–1625.
131. Chazaud, B., Inflammation during skeletal muscle regeneration and tissue remodeling: application to exercise-induced muscle damage management. Immunol Cell Biol 94 (2016), 140–145.
132. Saini, J., McPhee, J.S., Al-Dabbagh, S., Stewart, C.E., Al-Shanti, N., Regenerative function of immune system: modulation of muscle stem cells. Ageing Res Rev 27 (2016), 67–76.
133. Rayavarapu, S., Coley, W., Van der Meulen, J.H., Cakir, E., Tappeta, K., Kinder, T.B., et al. Activation of the ubiquitin proteasome pathway in a mouse model of inflammatory myopathy: a potential therapeutic target. Arthritis Rheum 65 (2013), 3248–3258.
134. Rongvaux, A., Willinger, T., Martinek, J., Strowig, T., Gearty, S.V., Teichmann, L.L., et al. Development and function of human innate immune cells in a humanized mouse model. Nat Biotechnol 32 (2014), 364–372.
135. Shultz, L.D., Brehm, M.A., Garcia-Martinez, J.V., Greiner, D.L., Humanized mice for immune system investigation: progress, promise and challenges. Nat Rev Immunol 12 (2012), 786–798.
136. Shultz, L.D., Ishikawa, F., Greiner, D.L., Humanized mice in translational biomedical research. Nat Rev Immunol 7 (2007), 118–130.
137. Gomez, J.P., Gonçalves, C., Pichon, C., Midoux, P., Effect of IL-1β, TNF-α and IGF-1 on trans-endothelial passage of synthetic vectors through an in vitro vascular endothelial barrier of striated muscle. Gene Ther 24:7 (Jul. 2017), 416–424.
138. Sano, H., Sano, Y., Ishiguchi, E., Shimizu, F., Omoto, M., Maeda, T., et al. Establishment of a new conditionally immortalized human skeletal muscle microvascular endothelial cell line. J Cell Physiol 232 (2017), 3286–3295.
139. Tews, D.S., Goebel, H.H., Expression of cell adhesion molecules in inflammatory myopathies. J Neuroimmunol 59 (1995), 185–194.
140. Cid, M.C., Grau, J.M., Casademont, J., Tobias, E., Picazo, A., Coll-Vinent, B., et al. Leucocyte/endothelial cell adhesion receptors in muscle biopsies from patients with idiopathic inflammatory myopathies (IIM). Clin Exp Immunol 104 (1996), 467–473.
141. Liprandi, A., Bartoli, C., Figarella-Branger, D., Pellissier, J.F., Lepidi, H., Local expression of monocyte chemoattractant protein-1 (MCP-1) in idiopathic inflammatory myopathies. Acta Neuropathol 97 (1999), 642–648.
142. Jimi, T., Wakayama, Y., Murahashi, M., Inoue, M., Shibuya, S., Yamashita, S., et al. Expression of selectin families and their ligand sialyl Lewis X in the muscles of inflammatory myopathies: an immunohistochemical study. Intern Med 38 (1999), 632–635.
143. Tournadre, A., Dubost, J.J., Soubrier, M., Ruivard, M., Souteyrand, P., Schmidt, J., et al. Soluble IL-2 receptor: a biomarker for assessing myositis activity. Dis Markers, 2014, 2014, 472624.
144. Wolf, R.E., Baethge, B.A., Interleukin-1 alpha, interleukin-2, and soluble interleukin-2 receptors in polymyositis. Arthritis Rheum 33 (1990), 1007–1014.
145. Tokano, Y., Kanai, Y., Hashimoto, H., Okumura, K., Hirose, S., Soluble interleukin 2 receptors in patients with polymyositis/dermatomyositis. Ann Rheum Dis 51 (1992), 781–782.
146. Chevrel, G., Page, G., Granet, C., Streichenberger, N., Varennes, A., Miossec, P., Interleukin-17 increases the effects of IL-1 beta on muscle cells: arguments for the role of T cells in the pathogenesis of myositis. J Neuroimmunol 137 (2003), 125–133.
147. Kondo, M., Murakawa, Y., Harashima, N., Kobayashi, S., Yamaguchi, S., Harada, M., Roles of proinflammatory cytokines and the Fas/Fas ligand interaction in the pathogenesis of inflammatory myopathies. Immunology 128 (2009), e589–99.
148. Noda, S., Koike, H., Maeshima, S., Nakanishi, H., Iijima, M., Matsuo, K., et al. Transforming growth factor-beta signaling is upregulated in sporadic inclusion body myositis. Muscle Nerve 55:5 (May 2017), 741–747.